THERACART+
Investigation of Biological Activity of Mesenchymal Stem Cell-Derived Products for Osteoarthritis
The project “Investigation of Biological Activity of Mesenchymal Stem Cell-Derived Products for Osteoarthritis” (THERACART+) aims to develop an Advanced Therapy Medicinal Product (ATMP) for this degenerative disease, based on adipose-derived MSCs as autologous regenerative cell therapy.
The final product consisting of suspension of functional MSCs in a syringe for intra-articular injection was named CARTIL-S. The work packages (WPs) include characterizing the biopsy collection and downstream processing method to establish an optimized culture, developing a method for functional characterization of expanded MSCs (potency assays), holistic protein characterization of the MSC secretome (dubbed “medicinal signaling”) by Proteomics, completing preclinical studies, collecting and evaluating results, promoting innovation in SMEs, and drafting a feasibility study for clinical development.
The project is implemented within the framework of the National Recovery and Resilience Plan “Greece 2.0,” funded by the European Union – NextGenerationEU.